Exagen (XGN) EBT (2018 - 2026)

Exagen (XGN) has 9 years of EBT data on file, last reported at -$3.9 million in Q1 2026.

• Quarterly EBT fell 4.77% year-over-year to -$3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.1 million (down 29.58% YoY) and the FY2025 annual result came in at -$19.9 million, down 31.76% from the prior year.
• EBT improved to -$3.9 million in Q1 2026, from -$4.7 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$3.0 million in Q2 2024 to a low of -$17.3 million in Q1 2022.
• A 5-year average of -$7.1 million and a median of -$5.0 million in 2024 frame the typical range for EBT.
• Annual changes were most pronounced in 2022 — EBT slumped 179.03% — and 2023, when it soared 69.94%.
• Tracing XGN's EBT over 5 years: stood at -$14.4 million in 2022, then jumped by 62.68% to -$5.4 million in 2023, then jumped by 30.25% to -$3.7 million in 2024, then fell by 24.3% to -$4.7 million in 2025, then gained by 15.64% to -$3.9 million in 2026.
• The last three EBT figures came in at -$3.9 million (Q1 2026), -$4.7 million (Q4 2025), and -$7.1 million (Q3 2025), per Business Quant data.